Telesis Bio, Inc.

Telesis Bio, Inc.

OOTC:TBIO
0.01
USD
0.00
(0.00%)
-28.05EPS
6.47MMarket Cap
Nov 17Next Earn

Total Valuation

USD

As of June 30, 2024, Telesis Bio, Inc. carries a market capitalization of 6.47M, placing it among publicly traded companies globally. Its enterprise value stands at 62.29M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap6.47M
Enterprise Value62.29M

Important Dates

Telesis Bio, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

Earnings Date11/17/2026

Share Statistics

As of June 30, 2024, Telesis Bio, Inc. has 1.77M shares outstanding.

Shares Outstanding1.77M

Valuation Ratios

These figures are as of June 30, 2024. The price-to-sales ratio is 0.36, and the price-to-book ratio stands at -0.32.

PS Ratio0.36
PB Ratio-0.32
P/TBV Ratio-0.26
P/FCF Ratio-0.28
P/OCF Ratio-0.29

Enterprise Valuation

These figures are as of June 30, 2024. The EV/Sales ratio of 3.55 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 62.29M versus a market cap of 6.47M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.55

Financial Position

As of June 30, 2024, Telesis Bio, Inc. maintains a current ratio of 1.89, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 357.46, indicating elevated leverage, while an interest coverage ratio of -14.59 demonstrates limited ability to service its debt obligations.

Current Ratio1.89
Quick Ratio1.44
Debt / Equity357.46
Debt / EBITDA-0.82
Interest Coverage-14.59

Financial Efficiency

USD

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -59.24, reflecting losses generated across the asset base. The company generates approximately 102,520.47 in revenue per employee across its workforce of 171.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.50 indicates how many times Telesis Bio, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-59.24
Revenue Per Employee102,520.47
Employee Count171.00
Inventory Turnover3.50

Taxes

USD

Over the twelve months ended June 30, 2024, Telesis Bio, Inc. recorded 20,000.00 in income tax expense. The company reported a pretax loss of -48.50M and -49.54M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax20,000.00

Stock Price Statistics

USD

As of the close on November 12, 2026, Telesis Bio, Inc.'s stock has declined approximately 52.38% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.28.

52-Week Price Change-52.38%
50-Day Moving Average0.03
200-Day Moving Average0.28

Income Statement

USD

Over the twelve months ended June 30, 2024, Telesis Bio, Inc. generated 17.53M in revenue and converted that into -49.54M in net income, yielding earnings per share of -28.05. EBITDA reached -43.10M, while operating income came in at -35.21M.

Revenue17.53M
Gross Profit8.39M
Operating Income-35.21M
Pretax Income-48.50M
Net Income-49.54M
EBITDA-43.10M
EBIT-47.61M
Earnings Per Share (EPS)-28.05

Balance Sheet

USD

As of June 30, 2024, Telesis Bio, Inc. holds 10.21M in cash and equivalents against 35.55M in total debt, resulting in a net debt position of -1.12M. Total book value stands at -20.53M, with working capital of 7.14M providing operational flexibility.

Cash & Cash Equivalents10.21M
Total Debt35.55M
Net Debt-1.12M
Equity (Book Value)-20.53M
Book Value Per Share-11.58
Working Capital7.14M

Cash Flow

USD

Telesis Bio, Inc. produced -21.78M in operating cash flow over the twelve months ended June 30, 2024. After subtracting -1.01M in capital expenditures, free cash flow totaled -22.79M - equivalent to -13.18 per share.

Operating Cash Flow-21.78M
Capital Expenditures-1.01M
Free Cash Flow-22.79M
FCF Per Share-13.18

Margins

Over the twelve months ended June 30, 2024, Telesis Bio, Inc. posted a gross margin of 47.88, reflecting its pricing power and cost economics. The operating margin of -200.83 and net profit margin of -282.59 provide insight into operational efficiency.

Gross Margin47.88
Operating Margin-200.83
Pretax Margin-276.63
Profit Margin-282.59
EBITDA Margin-245.83

Dividends & Yields

These figures cover the twelve months ended June 30, 2024. The dividend payout ratio of 4.58 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -361.09: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 234.21, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Telesis Bio, Inc. shareholders.

Payout Ratio4.58
Shareholder Yield234.21
FCF Yield-361.09

Stock Splits

Telesis Bio, Inc.'s most recent stock split took place on May 9, 2024 with a 18:1 split ratio.

Last Split Date5/9/2024
Split Ratio18:1

Scores

As of June 30, 2024, Telesis Bio, Inc. has an Altman Z-Score of -7.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-7.04